AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03360526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TESA
Description: Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection.
Study NCT02830230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab cefixime,Tab Azithromycin
Description: The women with clinical cervicitis will receive treatment for cervicitis.
Study NCT01467570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral rehydration solution Hipp ORS Apple 200
Description: Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)
Study NCT01467570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ESPGHAN ORS
Description: Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)
Study NCT03512626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiVis, Aaren Scientific
Description: All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
Study NCT03512626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal IOL
Description: All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
Study NCT02713243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Capsules containing LJN452
Study NCT02713243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to LJN452
Description: Capsules containing placebo to LJN452
Study NCT02617173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro 400 Matrix Therapy Products
Description: Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
Study NCT04009954 — intervention group
Intervention type: OTHER
Intervention: Fecal and blood samples collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs).
Study NCT04090684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Ciprofloxacin/Celecoxib
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
Study NCT01746563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection
Study NCT04006639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic Technique
Description: Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
Study NCT00080912 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given in a single fraction or multiple fractions
Study NCT00080912 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given in a single fraction or multiple fractions
Study NCT01837901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrostimulation
Study NCT01746563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Laser therapy
Study NCT01746563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Laser therapy
Study NCT01837901 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcorneal electrostimulation
Study NCT01401764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Formulation buffers
Description: Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
Study NCT03077737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Change
Description: Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
Study NCT03077737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
Study NCT04573361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic care (one visit)
Description: One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
Study NCT04573361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic care (more than one visit)
Description: More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
Study NCT03095482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
Study NCT03095482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In vivo exposure therapy
Description: Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
Study NCT04247113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-based prevention following bariatric surgery
Description: PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
Study NCT00733421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: 90 mg once daily
Study NCT03095482 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: In vivo exposure therapy
Description: Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
Study NCT01253889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 25% oral solution
Description: 0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
Study NCT01253889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral water
Description: 0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
Study NCT02501031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ground flaxseed
Description: 2 tablespoons of ground flaxseed taken daily for approximately 50 days.
Study NCT02245360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phleum pratense grass pollen allergen extract
Description: Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
Study NCT02245360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet given once daily over 60 days
Study NCT03179501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: NP001
Study NCT03179501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT00918229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: balloon implant
Description: Absorbable perirectal spacer implantation
Study NCT00918229 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Balloon implantation
Description: Implantation of the balloon between the prostate and the anterior rectal wall
Study NCT03582007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Murepavadin
Description: Murepavadin + ertapenem
Study NCT03582007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One anti-pseudomonal antibiotic
Description: Either meropenem or piperacillin-tazobactam
Study NCT02841605 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rectosigmoidoscopy with colonic biopsies
Description: Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
Study NCT02841605 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy with colonic biopsies
Description: Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
Study NCT05043727 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exer gaming
Description: exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
Study NCT05043727 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment plan
Description: it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
Study NCT03978169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pleuropulmonary ultrasound
Description: three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
Study NCT00973856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PURELL VF481
Description: One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Study NCT00973856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PURELL VF481
Description: One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Study NCT00973856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Solution
Description: One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Study NCT00973856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Study NCT03060031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
Study NCT03060031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
Study NCT02726217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareSmarts Mobile Health Diabetes Program
Description: Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
Study NCT02726217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Reminders and Self Assessments
Study NCT02726217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Reminders and Self Assessments
Study NCT00944437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
Study NCT04107090 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lung recruitment maneuver
Description: Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
Study NCT04107090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung recruitment maneuver
Description: Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
Study NCT04107090 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tracheal IL-6 level
Description: tracheal IL-6 level was measured before and after recruitment maneuver
Study NCT04107090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tracheal IL-6 level
Description: tracheal IL-6 level was measured before and after recruitment maneuver
Study NCT04107090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US guided lung recruitment maneuver
Description: Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
Study NCT00147966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: treatment with rituximab
Study NCT00944437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full-face mask
Description: Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
Study NCT02790385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Study NCT02790385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Gauze Treatment
Study NCT01806337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Consolidation after CHOP induction
Study NCT02888405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Study NCT02888405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Study NCT04039516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: A total of 4 infusions of Lutathera to be administered every 8 weeks.
Study NCT00987298 — intervention group
Intervention type: DEVICE
Intervention: Visceral fat mass measurement
Description: Total body DXA measurement, Abdominal CT scan
Study NCT04679220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preheating
Description: For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
Study NCT04679220 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Preheating
Description: For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
Study NCT01165281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: One 5 mg to 40 mg capsule twice daily for 4 weeks.
Study NCT01165281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R331333 (referred to as JNS024 ER or CG5503)
Description: One 25 mg to 200 mg capsule twice daily for 4 weeks.
Study NCT05450874 — intervention group
Intervention type: PROCEDURE
Intervention: hepatectomy
Study NCT00364858 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cerezyme
Description: Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
Study NCT00326378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy with Docetaxel plus cisplatin
Description: definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
Study NCT00326378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCRT arm without consolidation chemotherapy
Description: definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
Study NCT01468402 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Image
Description: The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
Study NCT00581529 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
Study NCT04936022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
Study NCT04936022 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care lifestyle advice
Description: Healthy lifestyle advice for hypertension, given by a healthcare professional.
Study NCT04936022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care lifestyle advice
Description: Healthy lifestyle advice for hypertension, given by a healthcare professional.
Study NCT01274546 — intervention group
Intervention type: DEVICE
Intervention: cruciate-retaining Foundation Knee system
Description: subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Study NCT03900286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Dietary Replacement
Description: Total Dietary Replacement
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT01774695 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Increased physical activity
Description: The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week.
Study NCT01222715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01222715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01222715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01222715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV